Boston, MASSACHUSETTS4 Active Studies

Diffuse Large B-Cell Lymphoma Clinical Trials in Boston, MASSACHUSETTS

Find 4 actively recruiting diffuse large b-cell lymphoma clinical trials in Boston, MASSACHUSETTS. Connect with local research sites and explore new treatment options.

4
Active Trials
4
Sponsors
616
Enrolling

Recruiting Diffuse Large B-Cell Lymphoma Studies in Boston

RecruitingBoston, MASSACHUSETTSNCT05139017

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standa...

290 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBoston, MASSACHUSETTSNCT02227251

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated cli...

244 participants
Karyopharm Therapeutics Inc
View Study Details
RecruitingBoston, MASSACHUSETTSNCT05905328

Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy

This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with ...

54 participants
CytoAgents, Inc.
View Study Details
RecruitingBoston, MASSACHUSETTSNCT06550141

Emapalumab Prevention of CAR-T Cell Associated Toxicities

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research s...

28 participants
Marcela V. Maus, M.D.,Ph.D.
View Study Details

About Diffuse Large B-Cell Lymphoma Clinical Trials in Boston

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for about 30% of cases. It is an aggressive lymphoma that grows rapidly. Treatment usually involves chemoimmunotherapy, with CAR-T cell therapy for relapsed cases.

There are currently 4 diffuse large b-cell lymphoma clinical trials recruiting participants in Boston, MASSACHUSETTS. These studies are seeking a combined 616 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Karyopharm Therapeutics Inc, CytoAgents, Inc. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Diffuse Large B-Cell Lymphoma Clinical Trials in Boston — FAQ

Are there diffuse large b-cell lymphoma clinical trials in Boston?

Yes, there are 4 diffuse large b-cell lymphoma clinical trials currently recruiting in Boston, MASSACHUSETTS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What diffuse large b-cell lymphoma treatments are being tested?

The 4 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for diffuse large b-cell lymphoma.

Data updated March 2, 2026 from ClinicalTrials.gov